Literature DB >> 10501700

[Epithelial tumors of the kidney. Pathological subtyping and cytogenetic correlation].

S Störkel1.   

Abstract

The recent new morphological classification of epithelial renal tumors has overcome the former unspecified adenoma and carcinoma classification by introducing a specific subtyping. Today we divide in oncocytic and metanephrogenic renal cell adenomas, clear cell-, papillary-, chromophobe-, and collecting duct associated renal cell carcinomas, and transitional cell- and neuroendocrine renal carcinomas. These entities are characterized by a definite immunohistological marker spectrum and differing histogenetic pathways. New cytogenetic data have proven specific chromosomal aberrations for the different tumor types and have confirmed the morphological classification. Certain genetic changes are correlated to specific pathological phenotypes especially in oncocytic tumors. It is possible now to propose an in part hypothetical kidney tumor model which describes the development and progression of adenomas and carcinomas of the kidney in an adenoma-carcinoma sequence.

Entities:  

Mesh:

Year:  1999        PMID: 10501700     DOI: 10.1007/s001200050310

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  3 in total

1.  Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses.

Authors:  Aliaksei Chyhrai; Jimsgene Sanjmyatav; Mieczyslaw Gajda; Olaf Reichelt; Heiko Wunderlich; Thomas Steiner; Enis Tanović; Kerstin Junker
Journal:  World J Urol       Date:  2010-06       Impact factor: 4.226

2.  Contrast enhanced ultrasound of renal masses.

Authors:  Andre Ignee; Bernd Straub; Gudrun Schuessler; Christoph Frank Dietrich
Journal:  World J Radiol       Date:  2010-01-28

3.  [Tumor profiling of renal cell tumors: relevance for diagnostics and therapy].

Authors:  K Junker; T Steiner; J Sanjmyatav; R Pilchowski; C Heinze; M Walter; J Schubert
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.